Prosight Management, LP Cytom X Therapeutics, Inc. Transaction History
Prosight Management, LP
- $372 Million
- Q3 2024
A detailed history of Prosight Management, LP transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Prosight Management, LP holds 3,022,109 shares of CTMX stock, worth $2.75 Million. This represents 0.96% of its overall portfolio holdings.
Number of Shares
3,022,109Holding current value
$2.75 Million% of portfolio
0.96%Shares
1 transactions
Others Institutions Holding CTMX
# of Institutions
69Shares Held
50.4MCall Options Held
112KPut Options Held
8.3K-
Tang Capital Management LLC San Diego, CA7.81MShares$7.11 Million0.79% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$4.76 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.16MShares$4.7 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X04.81MShares$4.38 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.1MShares$2.82 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $60M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...